In a 19-year-old male receiving trametinib as a fourth-line treatment for NF-1-associated glioblastoma, a complete response was achieved at 10 months, which was noted to be sustained at a 13-month clinic visit [137]. The gene discussed is NF1; the disease is glioblastoma.